Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483411 | 1.00 | CPB2 (0.44) | CPB2GSRRNPEPCA1CA2 | |
| SCHEMBL19483329 | 1.00 | CPB2 (0.44) | CPB2GSRRNPEPCA1CA2 | |
| SCHEMBL19483410 | 0.94 | CPB2 (0.44) | CPB2GSRRNPEPCA1CA2 | |
| SCHEMBL19483409 | 0.94 | CPB2 (0.44) | CPB2GSRRNPEPCA1CA2 | |
| SCHEMBL19483416 | 0.92 | CPB2 (0.47) | CPB2GSRRNPEPPAOX | |
| SCHEMBL19483403 | 0.92 | CPB2 (0.47) | CPB2GSRRNPEPPAOX | |
| SCHEMBL19483405 | 0.89 | GABRR1 (0.37) | CPB2GABRR1 | |
| SCHEMBL19483413 | 0.89 | GABRR1 (0.37) | CPB2GABRR1 | |
| SCHEMBL23876022 | 0.81 | CA2 (0.48) | CA1CA2 | |
| SCHEMBL19483418 | 0.80 | GABRR1 (0.34) | GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | CPB2 236/4885GSR 3570/4885RNPEP 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.